In an editorial in ‘Radiology’ dated February 2018, Matthew S. Davenport, MD of the Department of Radiology, University of Michigan in Ann Arbor, discussed the risks and benefits of using gadolinium-based MRI contrast agents. He stated that “when it was discovered that gadolinium in gadolinium-based contrast media was not excreted fully from the body, it threw the risk-benefit assessment of patients being considered for contrast material-enhanced magnetic resonance (MR) imaging into turmoil”. He went on to say that “...we now know that, regardless of renal function and apparently regardless of patient status or type of contrast agent, if a gadolinium-based contrast medium is administered, a very small quantity of that gadolinium will remain in the patient for an indeterminate and possibly long period of time”. Although the consequences of retained gadolinium are still unknown, the European Medicines Agency recently stated that the suspension of linear agents offer no or negligible clinically relevant benefit beyond those with lesser retention, i.e., macrocyclic agents and unknown but potentially important risk. Davenport presents a table of risks and benefits of gadolinium-based contrast agents and states that “...the decision making involved when selecting an agent is complicated and difficult to reduce to a single issue”. He voices a concern for a switch to the use of macrocyclics vs linear agents given that the rate of severe allergic reactions from macrocyclics is higher. The editorial goes on to state that we “remain in a state of ignorance with respect to gadolinium retention and clinical harm. Clarifying the risk of gadolinium retention in patients with normal or near-normal renal function (i.e, the vast majority of patients being imaged) is an urgent priority that must be pursued to better inform the decision-making process”. To read Dr. Davenport’s editorial in full please visit: http://pubs.rsna.org/doi/full/10.1148/radiol.2017172224 Please join the growing list of advocates and sign our petition so we can help promote the development of safer alternatives and effective treatments to remove gadolinium from patients affected by it.